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Background
V-1 Immunitor (V1) is a therapeutic AIDS vaccine for-
mulated as an oral pill comprising heat-inactivated HIV
antigens derived from pooled blood of HIV-positive
donors. Several studies carried out in Thailand have
reported beneficial effects of V1 in AIDS patients
including the increase in CD4 counts; decrease in viral
load; body weight gain; improved clinical symptoms; and
extended survival. The goal of our study was to sub-
stantiate these effects independently in another country.
Methods
We have tested V1 in seven randomly chosen HIV-
positive patients at our regional AIDS Center. Five
patients were therapy naïve patients but two have been
receiving HAART during study period. Patients were
a d m i n i s t e r e do n eV 1p i l lp e rd a yf o rt h r e em o n t h s .
Results
No adverse effects due to V1 administration were
observed at any time. The average increase in CD4-posi-
tive lymphocytes was 50 cells (22% or 228 vs 278; p =
0.055); absolute CD8 cell counts increased by 29 (8% or
356 vs 385; p = 0.03); plasma viral load as measured by
PCR decreased in all patients (p = 0.018 by Wilcoxon
signed-rank test); the average weight gain was 4.6 kg
(7.8% or 58.8 vs 64.4; p = 0.034). Clinical symptoms as
observed by physicians improved in all patients, includ-
ing three patients co-infected with hepatitis C virus.
Patient-reported outcomes, i.e., appetite, energy, mood,
and sense of well-being were also ameliorated.
Discussion
Despite small sample size, results of this study are statis-
tically significant and support unequivocally the results
of earlier trials in Thailand. Increase in CD4 counts and
decrease in viral load can serve as immune correlates of
vaccine efficacy in other AIDS vaccine clinical trials.
Surprisingly V1 benefited HCV co-infection as well.
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